Immunochina Secures Hundreds of Millions in Series D Financing to Advance China's First Commercially Developed Cell Therapy

VCBeat learned第一时间 that recently, Beijing Yimiao Shenzhou Medical Technology Co., Ltd. (referred to as "Yimiao Shenzhou") has successfully completed a D-round strategic financing of several hundred million yuan. This round of financing was led by China Life Healthcare Fund, with participation from GF Qianhe, Shuimu Shengan, and Yajie Angel, along with continued support from existing investors SDIC Venture and Longmen Fund. The proceeds of this financing will be used to accelerate clinical progress and commercial production development, promoting the company's IM19 as the first self-developed cell drug produced in China, addressing pain points in the cell therapy industry, and benefiting more patients in China. Meanwhile, it will expand its product pipeline represented by solid tumor and UCART products, helping the company become a leading innovative platform for gene and cell drugs.

"First of all, we sincerely thank China Life Equity and all new and existing shareholders for their trust and support in Yimiao Shenzhou. The successful completion of this round of financing has laid a more solid foundation for the company's rapid development in the future," said Dr. He Ting, CEO of Yimiao Shenzhou. "Since the beginning of this year, by leveraging our independent and leading advantages in the gene and cell field, the company has obtained the third clinical trial approval from the National Medical Products Administration, successively collaborated with Peking University Third Hospital and Beijing Cancer Hospital to co-build cell therapy R&D centers, significantly enhancing our clinical R&D capabilities. We are at the forefront of transforming scientific and technological achievements into practical applications and promoting industry-university-research collaboration. Currently, the company’s pipeline and industrialization efforts are accelerating, with several products in clinical research stages achieving significant progress. In the future, Yimiao Shenzhou will continue to explore scientific, practical, and cost-effective CAR-T process technologies, expand innovative product lines and indications, promote the transformation of CAR-T technology achievements, and better benefit a wide range of cancer patient populations."

Ms. Zhang Leidi, head of China Life Equity, stated: "Beijing Yimiaoshenzhou Medical Techology Co., Ltd. is one of the few cell therapy companies in China that can achieve full-process independent research and development as well as scaled production. It has achieved multiple industry-leading technological breakthroughs in production processes, analytical methods, large-scale preparation, and long-acting technologies. At the same time, the company boasts a product pipeline with both drug-like properties and innovative potential, showcasing outstanding technical capabilities within the industry. China Life Equity hopes to support Beijing Yimiaoshenzhou Medical Techology Co., Ltd. in continuously innovating in the field of cell therapy, bringing more accessible cell therapy products to patients domestically and internationally, and contributing greater efforts to advance national health care and social progress."

Beijing Yimiaoshenzhou Medical Techology Co., Ltd. was founded in 2015, headquartered in Beijing, and is committed to applying innovative gene-cell drug technology to the treatment of malignant tumors. The company owns an independent gene-cell drug R&D and industrialization platform, mastering core technologies such as large-scale plasmid preparation, lentiviral vector preparation, and primary immune cell preparation. Its R&D pipeline includes multiple CAR-T drugs for advanced cancer treatment and has obtained three IND approvals. The company has been recognized as a National High-tech Enterprise, received support from Beijing's major science and technology projects, and is qualified as a Frontier Technology Enterprise in Zhongguancun. The company’s management team has been honored with awards such as Beijing Science and Technology Nova, Zhongguancun High-end Leading Talent, and Beijing Haiying Talent.

Beijing Yimiaoshenzhou Medical Techology Co., Ltd. always adheres to the mission of "making cancer no longer an incurable disease," prioritizing quality and patients, upholding the values of "collaboration, dedication, hard work, and innovation," and striving to become "a world-class gene and cell drug enterprise."

China Life Equity Company was established in June 2016 as a specialized private equity investment platform under China Life. Adhering to the investment philosophy of "investing in the future, investing in innovation, and investing in value," the company fully leverages the professional advantages of insurance funds and China Life's sense of responsibility, serving national strategies, supporting the real economy, and demonstrating China Life's commitment. The China Life Healthcare Fund, initiated by China Life Equity Company, is a leading flagship medical and healthcare industry investment fund in China. Since its establishment, it has achieved extensive investment coverage in fields such as life sciences, medical technology, medical services, and digital healthcare.